Cargando…

Immune Infiltration in Invasive Lobular Breast Cancer

BACKGROUND: Invasive lobular breast cancer (ILC) is the second most common histological subtype of breast cancer after invasive ductal cancer (IDC). Here, we aimed at evaluating the prevalence, levels, and composition of tumor-infiltrating lymphocytes (TILs) and their association with clinico-pathol...

Descripción completa

Detalles Bibliográficos
Autores principales: Desmedt, Christine, Salgado, Roberto, Fornili, Marco, Pruneri, Giancarlo, Van den Eynden, Gert, Zoppoli, Gabriele, Rothé, Françoise, Buisseret, Laurence, Garaud, Soizic, Willard-Gallo, Karen, Brown, David, Bareche, Yacine, Rouas, Ghizlane, Galant, Christine, Bertucci, François, Loi, Sherene, Viale, Giuseppe, Di Leo, Angelo, Green, Andrew R, Ellis, Ian O, Rakha, Emad A, Larsimont, Denis, Biganzoli, Elia, Sotiriou, Christos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037125/
https://www.ncbi.nlm.nih.gov/pubmed/29471435
http://dx.doi.org/10.1093/jnci/djx268
_version_ 1783338284457394176
author Desmedt, Christine
Salgado, Roberto
Fornili, Marco
Pruneri, Giancarlo
Van den Eynden, Gert
Zoppoli, Gabriele
Rothé, Françoise
Buisseret, Laurence
Garaud, Soizic
Willard-Gallo, Karen
Brown, David
Bareche, Yacine
Rouas, Ghizlane
Galant, Christine
Bertucci, François
Loi, Sherene
Viale, Giuseppe
Di Leo, Angelo
Green, Andrew R
Ellis, Ian O
Rakha, Emad A
Larsimont, Denis
Biganzoli, Elia
Sotiriou, Christos
author_facet Desmedt, Christine
Salgado, Roberto
Fornili, Marco
Pruneri, Giancarlo
Van den Eynden, Gert
Zoppoli, Gabriele
Rothé, Françoise
Buisseret, Laurence
Garaud, Soizic
Willard-Gallo, Karen
Brown, David
Bareche, Yacine
Rouas, Ghizlane
Galant, Christine
Bertucci, François
Loi, Sherene
Viale, Giuseppe
Di Leo, Angelo
Green, Andrew R
Ellis, Ian O
Rakha, Emad A
Larsimont, Denis
Biganzoli, Elia
Sotiriou, Christos
author_sort Desmedt, Christine
collection PubMed
description BACKGROUND: Invasive lobular breast cancer (ILC) is the second most common histological subtype of breast cancer after invasive ductal cancer (IDC). Here, we aimed at evaluating the prevalence, levels, and composition of tumor-infiltrating lymphocytes (TILs) and their association with clinico-pathological and outcome variables in ILC, and to compare them with IDC. METHODS: We considered two patient series with TIL data: a multicentric retrospective series (n = 614) and the BIG 02-98 study (n = 149 ILC and 807 IDC). We compared immune subsets identified by immuno-histochemistry in the ILC (n = 159) and IDC (n = 468) patients from the Nottingham series, as well as the CIBERSORT immune profiling of the ILC (n = 98) and IDC (n = 388) METABRIC and The Cancer Genome Atlas patients. All ILC/IDC comparisons were done in estrogen receptor (ER)–positive/human epidermal growth factor receptor 2 (HER2)–negative tumors. All statistical tests were two-sided. RESULTS: TIL levels were statistically significantly lower in ILC compared with IDC (fold-change = 0.79, 95% confidence interval = 0.70 to 0.88, P < .001). In ILC, high TIL levels were associated with young age, lymph node involvement, and high proliferative tumors. In the univariate analysis, high TIL levels were associated with worse prognosis in the retrospective and BIG 02-98 lobular series, although they did not reach statistical significance in the latter. The Nottingham series revealed that the levels of intratumoral but not total CD8(+) were statistically significantly lower in ILC compared with IDC. Comparison of the CIBERSORT profiles highlighted statistically significant differences in terms of immune composition. CONCLUSIONS: This study shows differences between the immune infiltrates of ER-positive/HER2-negative ILC and IDC in terms of prevalence, levels, localization, composition, and clinical associations.
format Online
Article
Text
id pubmed-6037125
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-60371252018-07-12 Immune Infiltration in Invasive Lobular Breast Cancer Desmedt, Christine Salgado, Roberto Fornili, Marco Pruneri, Giancarlo Van den Eynden, Gert Zoppoli, Gabriele Rothé, Françoise Buisseret, Laurence Garaud, Soizic Willard-Gallo, Karen Brown, David Bareche, Yacine Rouas, Ghizlane Galant, Christine Bertucci, François Loi, Sherene Viale, Giuseppe Di Leo, Angelo Green, Andrew R Ellis, Ian O Rakha, Emad A Larsimont, Denis Biganzoli, Elia Sotiriou, Christos J Natl Cancer Inst Articles BACKGROUND: Invasive lobular breast cancer (ILC) is the second most common histological subtype of breast cancer after invasive ductal cancer (IDC). Here, we aimed at evaluating the prevalence, levels, and composition of tumor-infiltrating lymphocytes (TILs) and their association with clinico-pathological and outcome variables in ILC, and to compare them with IDC. METHODS: We considered two patient series with TIL data: a multicentric retrospective series (n = 614) and the BIG 02-98 study (n = 149 ILC and 807 IDC). We compared immune subsets identified by immuno-histochemistry in the ILC (n = 159) and IDC (n = 468) patients from the Nottingham series, as well as the CIBERSORT immune profiling of the ILC (n = 98) and IDC (n = 388) METABRIC and The Cancer Genome Atlas patients. All ILC/IDC comparisons were done in estrogen receptor (ER)–positive/human epidermal growth factor receptor 2 (HER2)–negative tumors. All statistical tests were two-sided. RESULTS: TIL levels were statistically significantly lower in ILC compared with IDC (fold-change = 0.79, 95% confidence interval = 0.70 to 0.88, P < .001). In ILC, high TIL levels were associated with young age, lymph node involvement, and high proliferative tumors. In the univariate analysis, high TIL levels were associated with worse prognosis in the retrospective and BIG 02-98 lobular series, although they did not reach statistical significance in the latter. The Nottingham series revealed that the levels of intratumoral but not total CD8(+) were statistically significantly lower in ILC compared with IDC. Comparison of the CIBERSORT profiles highlighted statistically significant differences in terms of immune composition. CONCLUSIONS: This study shows differences between the immune infiltrates of ER-positive/HER2-negative ILC and IDC in terms of prevalence, levels, localization, composition, and clinical associations. Oxford University Press 2018-02-20 /pmc/articles/PMC6037125/ /pubmed/29471435 http://dx.doi.org/10.1093/jnci/djx268 Text en © The Author(s) 2018. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Articles
Desmedt, Christine
Salgado, Roberto
Fornili, Marco
Pruneri, Giancarlo
Van den Eynden, Gert
Zoppoli, Gabriele
Rothé, Françoise
Buisseret, Laurence
Garaud, Soizic
Willard-Gallo, Karen
Brown, David
Bareche, Yacine
Rouas, Ghizlane
Galant, Christine
Bertucci, François
Loi, Sherene
Viale, Giuseppe
Di Leo, Angelo
Green, Andrew R
Ellis, Ian O
Rakha, Emad A
Larsimont, Denis
Biganzoli, Elia
Sotiriou, Christos
Immune Infiltration in Invasive Lobular Breast Cancer
title Immune Infiltration in Invasive Lobular Breast Cancer
title_full Immune Infiltration in Invasive Lobular Breast Cancer
title_fullStr Immune Infiltration in Invasive Lobular Breast Cancer
title_full_unstemmed Immune Infiltration in Invasive Lobular Breast Cancer
title_short Immune Infiltration in Invasive Lobular Breast Cancer
title_sort immune infiltration in invasive lobular breast cancer
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037125/
https://www.ncbi.nlm.nih.gov/pubmed/29471435
http://dx.doi.org/10.1093/jnci/djx268
work_keys_str_mv AT desmedtchristine immuneinfiltrationininvasivelobularbreastcancer
AT salgadoroberto immuneinfiltrationininvasivelobularbreastcancer
AT fornilimarco immuneinfiltrationininvasivelobularbreastcancer
AT prunerigiancarlo immuneinfiltrationininvasivelobularbreastcancer
AT vandeneyndengert immuneinfiltrationininvasivelobularbreastcancer
AT zoppoligabriele immuneinfiltrationininvasivelobularbreastcancer
AT rothefrancoise immuneinfiltrationininvasivelobularbreastcancer
AT buisseretlaurence immuneinfiltrationininvasivelobularbreastcancer
AT garaudsoizic immuneinfiltrationininvasivelobularbreastcancer
AT willardgallokaren immuneinfiltrationininvasivelobularbreastcancer
AT browndavid immuneinfiltrationininvasivelobularbreastcancer
AT barecheyacine immuneinfiltrationininvasivelobularbreastcancer
AT rouasghizlane immuneinfiltrationininvasivelobularbreastcancer
AT galantchristine immuneinfiltrationininvasivelobularbreastcancer
AT bertuccifrancois immuneinfiltrationininvasivelobularbreastcancer
AT loisherene immuneinfiltrationininvasivelobularbreastcancer
AT vialegiuseppe immuneinfiltrationininvasivelobularbreastcancer
AT dileoangelo immuneinfiltrationininvasivelobularbreastcancer
AT greenandrewr immuneinfiltrationininvasivelobularbreastcancer
AT ellisiano immuneinfiltrationininvasivelobularbreastcancer
AT rakhaemada immuneinfiltrationininvasivelobularbreastcancer
AT larsimontdenis immuneinfiltrationininvasivelobularbreastcancer
AT biganzolielia immuneinfiltrationininvasivelobularbreastcancer
AT sotiriouchristos immuneinfiltrationininvasivelobularbreastcancer